Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EDITNASDAQ:ELEVNASDAQ:FATENASDAQ:IPSCNYSE:JNJNASDAQ:YMAB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEDITEditas Medicine$1.25-3.8%$1.51$1.12▼$7.41$103.72M1.882.55 million shs1.14 million shsELEVElevation Oncology$0.260.0%$0.55$0.24▼$5.83$15.40M1.371.34 million shs1.76 million shsFATEFate Therapeutics$0.85-3.7%$1.17$0.83▼$7.35$97.33M2.262.29 million shs890,602 shsIPSCCentury Therapeutics$0.51-6.5%$0.71$0.51▼$4.43$44.13M1.75384,662 shs297,599 shsJNJJohnson & Johnson$163.63+0.3%$158.68$140.68▼$169.99$394.32B0.477.63 million shs5.76 million shsYMABY-mAbs Therapeutics$4.81-3.0%$5.58$4.25▼$17.78$217.50M0.65333,807 shs164,220 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEDITEditas Medicine-3.85%-4.58%-32.07%+3.31%-83.20%ELEVElevation Oncology-0.04%-13.36%-52.73%-56.19%-94.81%FATEFate Therapeutics-3.66%-7.07%-26.78%-47.25%-88.43%IPSCCentury Therapeutics-6.47%-7.59%-26.04%-50.68%-87.99%JNJJohnson & Johnson+0.25%+0.14%+0.54%+12.81%+3.59%YMABY-mAbs Therapeutics-3.02%-3.80%-12.70%-39.88%-70.85%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEDITEditas Medicine3.9609 of 5 stars3.03.00.04.31.41.71.3ELEVElevation Oncology2.4254 of 5 stars4.22.00.00.01.01.70.6FATEFate Therapeutics3.8186 of 5 stars3.11.00.04.72.42.50.6IPSCCentury Therapeutics2.2796 of 5 stars3.52.00.00.02.51.70.6JNJJohnson & Johnson4.4003 of 5 stars2.33.04.23.93.52.50.6YMABY-mAbs Therapeutics3.7722 of 5 stars4.53.00.00.01.84.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEDITEditas Medicine 2.07Hold$6.83446.67% UpsideELEVElevation Oncology 2.30Hold$3.391,202.20% UpsideFATEFate Therapeutics 2.22Hold$5.43539.18% UpsideIPSCCentury Therapeutics 3.00Buy$5.00874.85% UpsideJNJJohnson & Johnson 2.56Moderate Buy$171.334.71% UpsideYMABY-mAbs Therapeutics 2.91Moderate Buy$18.30280.46% UpsideCurrent Analyst Ratings BreakdownLatest YMAB, IPSC, EDIT, FATE, JNJ, and ELEV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/28/2025IPSCCentury TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy3/24/2025ELEVElevation OncologyStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$5.00 ➝ $1.003/24/2025IPSCCentury TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $7.003/21/2025ELEVElevation OncologyCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeMarket Perform3/21/2025ELEVElevation OncologyLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform$9.00 ➝ $1.003/21/2025ELEVElevation OncologyCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform3/21/2025ELEVElevation OncologyPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral$10.00 ➝ $0.703/21/2025ELEVElevation OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $1.003/21/2025IPSCCentury TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $5.003/21/2025YMABY-mAbs TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$22.00 ➝ $12.003/20/2025ELEVElevation OncologyWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 3/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEDITEditas Medicine$32.31M3.21N/AN/A$4.27 per share0.29ELEVElevation OncologyN/AN/AN/AN/A$1.29 per shareN/AFATEFate Therapeutics$13.63M7.14N/AN/A$3.74 per share0.23IPSCCentury Therapeutics$6.59M6.70N/AN/A$3.06 per share0.17JNJJohnson & Johnson$88.82B4.44$13.45 per share12.17$29.69 per share5.51YMABY-mAbs Therapeutics$87.69M2.48N/AN/A$2.32 per share2.07Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEDITEditas Medicine-$153.22M-$2.88N/AN/AN/A-340.96%-80.13%-50.99%5/6/2025 (Estimated)ELEVElevation Oncology-$45.70M-$0.81N/AN/AN/AN/A-59.73%-40.05%5/1/2025 (Estimated)FATEFate Therapeutics-$160.93M-$1.64N/AN/AN/A-1,325.43%-45.88%-33.95%5/8/2025 (Estimated)IPSCCentury Therapeutics-$136.67M-$1.63N/AN/AN/A-4,837.73%-61.66%-31.78%5/8/2025 (Estimated)JNJJohnson & Johnson$14.07B$6.6524.6114.782.5618.20%34.24%13.63%4/15/2025 (Estimated)YMABY-mAbs Therapeutics-$21.43M-$0.67N/AN/AN/A-28.22%-24.61%-18.49%5/6/2025 (Estimated)Latest YMAB, IPSC, EDIT, FATE, JNJ, and ELEV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/15/2025N/AJNJJohnson & Johnson$2.59N/AN/AN/A$21.65 billionN/A3/19/2025Q4 2024IPSCCentury Therapeutics-$0.45-$0.43+$0.02-$0.43$0.67 million$4.18 million3/6/2025Q4 2024ELEVElevation Oncology-$0.22-$0.18+$0.04-$0.18N/AN/A3/5/2025Q4 2024EDITEditas Medicine-$0.39-$0.55-$0.16-$0.55$37.17 million$30.60 million3/5/2025Q4 2024FATEFate Therapeutics-$0.44-$0.31+$0.13-$0.44$1.57 million$1.86 million3/4/2025Q4 2024YMABY-mAbs Therapeutics-$0.13-$0.15-$0.02-$0.15$26.70 million$26.50 million1/22/2025Q4 2024JNJJohnson & Johnson$1.99$2.04+$0.05$1.41$22.44 billion$22.52 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEDITEditas MedicineN/AN/AN/AN/AN/AELEVElevation OncologyN/AN/AN/AN/AN/AFATEFate TherapeuticsN/AN/AN/AN/AN/AIPSCCentury TherapeuticsN/AN/AN/AN/AN/AJNJJohnson & Johnson$4.963.03%+5.43%74.59%63 YearsYMABY-mAbs TherapeuticsN/AN/AN/AN/AN/ALatest YMAB, IPSC, EDIT, FATE, JNJ, and ELEV DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date1/2/2025JNJJohnson & Johnsonquarterly$1.243.43%2/18/20252/18/20253/4/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEDITEditas MedicineN/A3.753.75ELEVElevation Oncology0.4517.7717.77FATEFate TherapeuticsN/A8.298.29IPSCCentury TherapeuticsN/A10.3910.39JNJJohnson & Johnson0.431.110.86YMABY-mAbs TherapeuticsN/A3.923.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEDITEditas Medicine71.90%ELEVElevation Oncology83.70%FATEFate Therapeutics97.54%IPSCCentury Therapeutics50.20%JNJJohnson & Johnson69.55%YMABY-mAbs Therapeutics70.85%Insider OwnershipCompanyInsider OwnershipEDITEditas Medicine1.90%ELEVElevation Oncology8.10%FATEFate Therapeutics5.00%IPSCCentury Therapeutics6.80%JNJJohnson & Johnson0.16%YMABY-mAbs Therapeutics22.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEDITEditas Medicine23082.98 million80.98 millionOptionableELEVElevation Oncology4059.22 million54.33 millionOptionableFATEFate Therapeutics550114.60 million108.20 millionOptionableIPSCCentury Therapeutics17086.05 million79.25 millionOptionableJNJJohnson & Johnson152,7002.41 billion2.40 billionOptionableYMABY-mAbs Therapeutics15045.22 million34.71 millionOptionableYMAB, IPSC, EDIT, FATE, JNJ, and ELEV HeadlinesRecent News About These CompaniesY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Average Recommendation of "Moderate Buy" from BrokeragesMarch 26 at 2:43 AM | americanbankingnews.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Rating of "Moderate Buy" by BrokeragesMarch 26 at 2:39 AM | marketbeat.comBreaking Down Y-mAbs Therapeutics: 5 Analysts Share Their ViewsMarch 23, 2025 | nasdaq.comHC Wainwright Cuts Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target to $12.00March 22, 2025 | marketbeat.comY-mAbs Therapeutics price target lowered to $12 from $22 at H.C. WainwrightMarch 21, 2025 | markets.businessinsider.com4YMAB : Breaking Down Y-mAbs Therapeutics: 5 Analysts Share Their ViewsMarch 21, 2025 | benzinga.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) CEO Sells $20,368.40 in StockMarch 12, 2025 | marketbeat.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Insider Thomas Gad Sells 10,810 SharesMarch 12, 2025 | marketbeat.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) CEO Michael J. Rossi Sells 3,917 SharesMarch 12, 2025 | insidertrades.comBearish: Analysts Just Cut Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Revenue and EPS estimatesMarch 9, 2025 | finance.yahoo.comYMAB FY2025 EPS Forecast Lowered by Cantor FitzgeraldMarch 8, 2025 | marketbeat.comQ1 EPS Estimate for Y-mAbs Therapeutics Boosted by AnalystMarch 8, 2025 | marketbeat.comWedbush Equities Analysts Lower Earnings Estimates for YMABMarch 8, 2025 | marketbeat.comTruist Financial Cuts Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target to $18.00March 6, 2025 | marketbeat.comY-mAbs Therapeutics (NASDAQ:YMAB) Given New $12.00 Price Target at Bank of AmericaMarch 6, 2025 | marketbeat.comY-mAbs Therapeutics (NASDAQ:YMAB) Given New $7.00 Price Target at Morgan StanleyMarch 6, 2025 | marketbeat.comForecasting The Future: 4 Analyst Projections For Y-mAbs TherapeuticsMarch 5, 2025 | benzinga.comY-mAbs Therapeutics price target lowered to $12 from $14 at BofAMarch 5, 2025 | markets.businessinsider.comY-Mabs Therapeutics (YMAB) Gets a Buy from OppenheimerMarch 5, 2025 | markets.businessinsider.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q4 2024 Earnings Call TranscriptMarch 5, 2025 | msn.comY-mAbs Therapeutics, Inc. (YMAB) Q4 2024 Earnings Call TranscriptMarch 4, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesTaiwan Semi's $100 Billion Investment: Fate of the ChipmakersBy Gabriel Osorio-Mazilli | March 6, 2025View Taiwan Semi's $100 Billion Investment: Fate of the ChipmakersMediterranean Growth Monster: CAVA Keeps Surging—Buy the Dip?By Jea Yu | March 4, 2025View Mediterranean Growth Monster: CAVA Keeps Surging—Buy the Dip?Occidental’s Billion-Dollar Carbon Credit Plan Takes ShapeBy Jea Yu | March 26, 2025View Occidental’s Billion-Dollar Carbon Credit Plan Takes ShapeRetail Sales Data Signals a Surge: The E-Commerce Stock PicksBy Gabriel Osorio-Mazilli | March 19, 2025View Retail Sales Data Signals a Surge: The E-Commerce Stock PicksUp 32% in 2025, Is Chinese E-Commerce Giant PDD Still a Buy?By Leo Miller | March 27, 2025View Up 32% in 2025, Is Chinese E-Commerce Giant PDD Still a Buy?YMAB, IPSC, EDIT, FATE, JNJ, and ELEV Company DescriptionsEditas Medicine NASDAQ:EDIT$1.25 -0.05 (-3.85%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$1.26 +0.01 (+0.80%) As of 03/28/2025 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.Elevation Oncology NASDAQ:ELEV$0.26 0.00 (-0.04%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$0.26 +0.00 (+1.15%) As of 03/28/2025 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.Fate Therapeutics NASDAQ:FATE$0.85 -0.03 (-3.66%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$0.87 +0.02 (+2.08%) As of 03/28/2025 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.Century Therapeutics NASDAQ:IPSC$0.51 -0.04 (-6.47%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$0.55 +0.04 (+7.43%) As of 03/28/2025 05:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.Johnson & Johnson NYSE:JNJ$163.63 +0.50 (+0.31%) Closing price 03/28/2025 03:59 PM EasternExtended Trading$163.36 -0.27 (-0.17%) As of 03/28/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.Y-mAbs Therapeutics NASDAQ:YMAB$4.81 -0.15 (-3.02%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$4.82 +0.01 (+0.10%) As of 03/28/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas JPMorgan: The 'NVIDIA of Banking' Poised for More Gains? Why Dollar Tree’s Family Dollar Sale Could Spark a Comeback Joby Aviation Stock: Analyst Confidence and Smart Money Align Ibotta Stock: Why the Buyback Looks Like a Bullish Bet Archer Aviation Stock Sees Surge in Institutional Buys How Can Tomahawk 6 Contribute to Broadcom's AI Growth Story? Microsoft’s Big Malaysia Bet Could Pay Off for Investors Intuitive Machines Gains After Earnings Beat, NASA Missions Ahead Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
